Yes. The HPV vaccine is safe and very effective against certain types of cancers. If started before a child’s 15th birthday, only two doses spaced 6-12 months apart are needed for protection.
Typically the HPV vaccine has been offered at the 11 or 12-year-old visit (when your adolescent is receiving their Tdap and MCV vaccines). However, the vaccine is approved for use at age 9 years, and the American Academy of Pediatrics states “The AAP recommends starting the series between 9 and 12 years, at an age that the provider deems optimal for acceptance and completion of the vaccination series.” Offering the vaccine earlier leaves ample time for discussion about the vaccine’s benefits and safety profile, and spreads out the number of vaccines a teen receives at age 11. The immune response is robust at age 9 years, and there is no current evidence of waning immunity of this vaccine. A retrospective study showed that participants were 22 times more likely to complete the HPV vaccine series when it was started at age 9 or 10, as compared to 11 or 12 years.
The HPV vaccine is actually recommended to all those under 26 years. And, in fact, many adults between the ages of 27-45 years are receiving the vaccine after discussing it with their doctors.
The HPV vaccine, approved by the FDA in June 2006 for girls as young as age 9, appears to be virtually 100% effective at preventing the two strains of HPV that account for about 70% of all cervical cancers. Cervical cancer is second only to breast cancer in the number of cancer diagnoses made each year in women. About a third of the cases are fatal. In fact, among teen girls, HPV infections with strains that cause warts have decreased 86% since the introduction of the vaccines. Among vaccinated women, cervical cancer has decreased by almost 40%! As a pediatrician whose wife has had breast cancer, I am moved by the suffering that might be prevented in my daughter and others in the next generation.
Most people have heard about the HPV vaccine as a way to prevent cancer of the cervix in girls/women. However, the HPV vaccine has many other benefits. Other diseases that the HPV vaccine can prevent include genital warts, cancer of the vulva, cancer of the penis (that can necessitate partial amputation of the penis to treat), and cancer of the mouth, lip, and tongue (which can necessitate disfiguring face, mouth or neck surgery and radiation). These other serious diseases can produce pain, suffering, decreased quality of life, reduced sexual function, and even death. I treat these diseases every day in my practice and am saddened to know that prevention could have avoided most of them.
A common fear of some parents about HPV vaccination is that it could encourage young girls to participate in promiscuous sexual behaviors, increasing teen pregnancy and sexually transmitted diseases. A 2012 article in Pediatrics has shown that over a period of 3 years after HPV vaccination in girls, there is no increase in pregnancy rates, sexually transmitted disease, or requests for contraceptive counseling. Another study from Michigan in 2019 also found similar results. The authors concluded that HPV vaccination status was not correlated or associated with initiation of sexual activity nor an increased number of sexual partners.
Based on all the benefits of the vaccine, both girls and boys should receive HPV vaccination between ages 11 and 12.
Bednarczyk, Robert A, et al. Sexual activity–related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics 2012; 130(5): 798-805.
Brouwer, A.F., Delinger, R.L., Eisenberg, M.C. et al. HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health 19.
Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012; 42(1):44–52
St. Sauver JL, et al. Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion Prev Med. 2016; 89:327-333.